Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹11,516 Cr revenue.
COGS 24.1%, employees 19.1%.
“Revenues were INR 3,302 crores up by 14%.”
“India business grew at 12% and Brazil grew at 21%.”
“It used to be twenty four months and today if you file a new dose here, it's going to be thirty six months.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 26.9%▲ | 10.5% |
| ROCE | 29.0%▲ | 13.8% |
| Net Margin | 18.0%▲ | 8.7% |
| EBITDA Margin | 31.8%▲ | 16.0% |
| Debt To Equity | 0.31x▲ | 0.21x |
| Rev Growth 3yr | 6.1%▲ | 5.8% |
| EPS Growth 3yr | 15.3%▲ | 3.6% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹12,742 Cr +10.6% | ₹11,516 Cr +7.3% | ₹10,728 Cr +11.5% | ₹9,620 Cr +13.1% | ₹8,508 Cr +6.3% | ₹8,005 Cr +0.8% | ₹7,939 Cr +3.5% | ₹7,673 Cr |
| Other Income | (₹95 Cr) ↓ Decline | ₹23 Cr -60.3% | ₹58 Cr +28.9% | ₹45 Cr -77.2% | ₹197 Cr +245.6% | ₹57 Cr -53.3% | ₹122 Cr +114.0% | ₹57 Cr |
| Total Income | ₹12,647 Cr +9.6% | ₹11,539 Cr +7.0% | ₹10,786 Cr +11.6% | ₹9,665 Cr +11.0% | ₹8,705 Cr +8.0% | ₹8,062 Cr +0.0% | ₹8,061 Cr +4.3% | ₹7,730 Cr |
| COGS | ₹3,104 Cr +11.8% | ₹2,776 Cr +3.4% | ₹2,686 Cr -1.8% | ₹2,735 Cr +12.0% | ₹2,443 Cr +13.8% | ₹2,147 Cr -0.9% | ₹2,167 Cr -2.3% | ₹2,219 Cr |
| ₹9,592 Cr +8.5% | ₹8,842 Cr +3.8% | ₹8,522 Cr +9.0% | ₹7,818 Cr +11.8% | ₹6,994 Cr +7.0% | ₹6,536 Cr -4.9% | ₹6,874 Cr +0.9% | ₹6,811 Cr | |
| Profit Before Tax | ₹3,008 Cr +12.5% | ₹2,673 Cr +13.6% | ₹2,352 Cr +27.3% | ₹1,847 Cr +50.7% | ₹1,226 Cr -19.7% | ₹1,526 Cr +28.6% | ₹1,187 Cr +111.2% | ₹562 Cr |
| Exceptional Items | (₹47 Cr) -95.8% | (₹24 Cr) ↓ Decline | ₹88 Cr | ₹0.00 Cr +100.0% | (₹485 Cr) | ₹0.00 Cr | ₹0.00 Cr +100.0% | (₹357 Cr) |
| ₹736 Cr -3.4% | ₹762 Cr +9.5% | ₹696 Cr +15.6% | ₹602 Cr +34.1% | ₹449 Cr +63.9% | ₹274 Cr +69.1% | ₹162 Cr +28.6% | ₹126 Cr | |
| Net Profit | ₹2,272 Cr +18.9% | ₹1,911 Cr +15.4% | ₹1,656 Cr +33.0% | ₹1,245 Cr +60.2% | ₹777 Cr -37.9% | ₹1,252 Cr +22.1% | ₹1,025 Cr +135.1% | ₹436 Cr |
| Profit (Owners) | ₹2,272 Cr +18.9% | ₹1,911 Cr +15.4% | ₹1,656 Cr +33.0% | ₹1,245 Cr +60.2% | ₹777 Cr -37.9% | ₹1,252 Cr +22.1% | ₹1,025 Cr +135.1% | ₹436 Cr |
| Other Comprehensive Income | (₹58 Cr) +37.6% | (₹93 Cr) ↓ Decline | ₹17 Cr ↑ Recovery | (₹137 Cr) ↓ Decline | ₹12 Cr -88.0% | ₹100 Cr ↑ Recovery | (₹192 Cr) ↓ Decline | ₹33 Cr |
| EPS | ₹67.12 | ₹56.46 | ₹48.93 | ₹36.79 | ₹22.96 | ₹36.99 | ₹30.29 | ₹12.88 |
| Diluted Shares | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr | ₹34 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Torrent Investments Limited (formerly known as Torrent Investments Private Limited) has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of In...
Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication - Newspaper Advertisement - Intimation of the 53rd AGM of the Company through VC / OAVM
Torrent Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 22, 2026.
Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "A Press Release on Financial Results which is being submitted to the media is also enclo...
Torrent Pharmaceuticals Limited has informed the Exchange about Investor Presentation
Torrent Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Torrent Pharmaceuticals Limited has informed the Exchange about Schedule of meet
Torrent Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Torrent Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Torrent Pharmaceuticals Limited has informed the Exchange regarding Notice of Court Convened General Meeting to be held on April 28, 2026
Torrent Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 21, 2026, titled " Torrent Pharma launches oral and injectable formulations of Semaglutide".
Torrent Pharmaceuticals Limited has informed the Exchange about Transcript
Torrent Pharmaceuticals Limited has informed the Exchange about Link of Recording